Dr. Mireia Pelegrin obtained her Veterinary degree in Barcelona. She next did a PhD at the Autonomous University of Barcelona focused on the development of transgenic mice as models of diabetes. In 1996, she moved to France for a post-doctoral training at the Institute of Molecular Genetics of Montpellier to work in the development of gene and cell therapy approaches for in vivo production of therapeutic monoclonal antibodies (mAbs), project that led to two international patents.
In 2000, Dr. Pelegrin became Senior Researcher at the CNRS in the same institute where she was a Project leader of a research program on antiviral immunotherapies.
She has a long-term experience in the study host-pathogens interactions as well as in antiviral immunotherapies.
Her group has pioneered the proof-of-concept that antiviral antibodies can induce long-term protective immunity (vaccinal effects).
In 2019, Dr. Pelegrin moved to the Institute for Regenerative Medicine and Biotherapies of Montpellier to lead the group “Antibodies and Immunomodulation”.
Her current work aims at deciphering and harnessing antibody-mediated immunomodulation mechanisms for therapeutic strategies.
She is a member of the Labex MabImprove and leads one the research axes of this French network focused in the improvement of mAb-based therapies. She is member of the Editorial Boards of “Emerging Microbes and Infections” and “Antibodies” journals.